

Claims:

1. Method of treating or preventing thromboses of a patient not induced by hyperhomocysteinuria or homocystinuria, said method comprising the step of administering a therapeutically effective amount of glycine betaine.
2. The method of claim 1, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.
3. The method of claim 1, in which the glycine betaine is administered by subcutaneous injection.
4. Method of treating or preventing thrombo-embolic trouble of a patient not induced by hyperhomocysteinuria or homocystinuria, said method comprising the step of administering a therapeutically effective amount of glycine betaine.
5. The method of claim 4, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.
6. The method of claim 4, in which the glycine betaine is administered by subcutaneous injection.
7. Method of treating or preventing blood coagulation disorders in a patient, said method comprising the step of administering a therapeutically effective amount of glycine betaine.
8. The method of claim 7, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.
9. The method of claim 7, in which the glycine betaine is administered by subcutaneous injection.
10. The method of claim 7, for the treatment or prevention of platelet aggregation disorders.
11. The method of claim 7, for the treatment or prevention of hemorrhage disorders.
12. Method of treating or preventing thromboses in a patient with haemorrhage risk, said method comprising the step of administering a therapeutically effective amount of glycine betaine.
13. The method of claim 12, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.
14. The method of claim 12, in which the glycine betaine is administered by subcutaneous injection.
15. Method of lysing thrombus in a patient, said method comprising the step of administering a therapeutically effective amount of glycine betaine.

16. The method of claim 15, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.

17. The method of claim 15, in which the glycine betaine is administered by subcutaneous injection.

18. Method of treating or preventing glycoprotein troubles in a patient, said method comprising the step of administering a therapeutically effective amount of glycine betaine as antagonist agent for the glycoprotein receptor.

19. The method of claim 18, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.

20. The method of claim 18, in which the glycine betaine is administered by subcutaneous injection.

21. The method of claim 18, in which the glycine betaine acts as antagonist for the glycoprotein IIb IIIa receptor.

22. Method of counteracting thrombo-embolic effects induced by a contrasting product administered to a patient, said method comprising the step of administering a therapeutically effective amount of glycine betaine.

23. The method of claim 22, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.

24. The method of claim 22, in which the glycine betaine is administered by subcutaneous injection.

25. A subcutaneous injectable pharmaceutical composition comprising water and therapeutically effective amount of glycine betaine.

26. A pharmaceutical combination comprising a therapeutically effective amount of an antithrombotic active agent inducing hemorrhagic side effect, and a therapeutically effective amount of glycine betaine for preventing or lessening said hemorrhagic side effect.

27. The composition of claim 26, in which glycine betaine is in a form suitable for subcutaneous injection.

28. A method for lessening the incidence of hemorrhagic side effects in a patient associated with the administration of an antithrombotic active agent other than glycine betaine, wherein the method comprises the step of administering an effective amount of glycine betaine.

29. The method of claim 28, in which the glycine betaine is administered with a pharmaceutically acceptable support, vehicle or excipient.

30. The method of claim 28, in which the glycine betaine is administered by subcutaneous injection.